Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1693
This examiner grants 41% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18041785 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | Non-Final OA | EMORY UNIVERSITY |
| 17773911 | 7-PYRIMIDINE-2-YL-OXY-INDAZOLE DERIVATIVES AND THEIR USE AS HERBICIDES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 17625020 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY | Non-Final OA | REGENTS OF THE UNIVERSITY OF MINNESOTA |
| 17502665 | Dietary Supplements and Composition for Treating Cancer | Non-Final OA | The Trustees of Princeton University |
| 18237624 | NASAL SPRAY USING PENTOSAN POLYSULFATE AND MUCOPOLYSACCHARIDE POLYSULFATE FOR COVID-19 PREVENTION AND TREATMENT | Non-Final OA | Rensselaer Polytechnic Institute |
| 17297586 | D-PSICOSE CRYSTAL AND PREPARATION METHOD THEREFOR | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 17594617 | PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP | Final Rejection | 3M INNOVATIVE PROPERTIES COMPANY |
| 18011341 | SAPONIN CONTAINING EXTRACTS PREPARED FROM HESPERALOE USEFUL IN THE TREATMENT OF NON-HUMAN ANIMALS | Non-Final OA | KIMBERLY-CLARK WORLDWIDE, INC. |
| 17478016 | REVERSIBLE MODIFICATION OF NUCLEOTIDES | Final Rejection | Illumina Cambridge Limited |
| 17999613 | COMPOSITION COMPRISING GLUCOSE OLIGOSACCHARIDE AND PROCESS FOR MAKING THE SAME AND USE THEREOF | Non-Final OA | CARGILL, INCORPORATED |
| 18004271 | CONJUGATION OF PROTEINS TO POLYSACCHARIDES USING A PHOSPHATE BRIDGE | Final Rejection | Wisconsin Alumni Research Foundation |
| 18577948 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy